Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Avivagen Announces the Appointment of Mr. Aubrey Dan to the Board of Directors


Posted on: 22 Nov 17

OTTAWA, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health,  is delighted to welcome Mr. Aubrey Dan to the Board of Directors.

Mr. Dan is a Canadian businessman, philanthropist and Tony-Award® winning theatre producer (MEMPHIS) as well as the Principal of the Dancap Family Investment Office (dancap.ca) and is also on the board of directors of Porter Airlines and CannTrust (CSE:TRST).

Following his graduation from Western University in 1985, Aubrey joined Novopharm Limited, one of the largest generic drug manufacturers in Canada, in the role of a sales representative and then progressing to Director of Sales. He later served as President of Wampole Canada Inc., a Novopharm subsidiary. Wampole is a herbal supplement and vitamin manufacturer. Novopharm was later acquired by Teva Pharmaceutical Industries Ltd. in 2000.

Kym Anthony, Avivagen’s Chairman & CEO commented: “We are both excited and delighted to have Aubrey Dan join our Board of Directors.  Aubrey brings a wealth of experience within the healthcare sector, as well as a tremendous business acumen for marketing and strategy, attributes which will both strengthen our board and help Avivagen achieve its true potential.”

Aubrey Dan commented, “I am always on the lookout for opportunities that are going to have a lasting, positive impact on society and where I can bring my knowledge and resources to support that vision. Following many months of due diligence and on reviewing opportunities to be actively involved in helping this company grow – both at the Board level and in support of the founders and management – I was delighted to accept the invitation to join the Board of Directors. Kym and I and the rest of the team already see many opportunities and we look forward to sharing those with our stakeholders at the appropriate time.”

The appointment of Mr. Dan as a director is subject to TSX Venture Exchange approval.

Additional Information about Mr. Aubrey Dan:
Aubrey is a generous philanthropist, donating millions of dollars, primarily to health and education charities, and other worthy causes. Together with his wife Marla, the Dans have donated millions to organizations that include: Sunnybrook Foundation for the Aubrey & Marla Dan Centre for Women and Babies ; University of Western Ontario to the DAN Department of Management and Organizational Studies; Baycrest Centre Foundation in on honor Marla's father, Reuben Cipin Healthy Living Community; Judy Dan Research and Treatment Centre (named in memory of Dan’s mother who passed away in 1995 due to Diabetic complications); University of Toronto, Leslie Dan Facility of Pharmacy in honour of his father. Most recently the Dans made a significant donation at Queen's University for the Dan School of Drama and Music as well as to the Tel Aviv University for the Dan Department of Communication.

Mr. Dan received an honorary Doctorate of Laws Degree (honoris causa) from Assumption University in 2008, and a Professional Achievement Award from Western University in 2015. He is a Governor at Tel Aviv University.

About Avivagen
Avivagen Inc. is a public Corporation traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.

About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Vivamune™ Health Chews (Vivamune)
Vivamune is an all-in-one chew that can dramatically simplify a pet’s supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient: OxC-beta™ compound, Vivamune targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune is available for sale in the US. For more information, visit www.vivamunehealth.com.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Statements relating to Avivagen’s ability to identify and capitalize on opportunities for its business and the ability of its products to fulfill the global mandate to remove all in-feed antibiotics as growth promoters are all forward-looking statements.

Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, risks relating to the following: Avivagen’s ability to continue as a going concern; whether the Corporation can expand its global regulatory advisor network in order to gain market approval of OxC-beta™; whether the Corporation can obtain market approval in additional geographies, if at all; whether it will be able to replace the antibiotics added to livestock feeds as growth promoters, whether it will confirm and expedite potential regulatory approvals of Avivagen’s OxC-beta™ for Livestock in major markets around the world, whether it will seek and be able to confirm the regulatory pathway for approvals in the U.S., Europe, South America and all other important markets, whether it will confirm, define and potentially expedite regulatory pathways for approval, whether any such approvals will be applied for or received in a timely manner or at all,  whether it will increase the market access of OxC-beta™ for Livestock, whether it will secure potential licensing and distribution partners in those markets and whether it can assure the full potential for the Corporation.   Avivagen may decide not to seek regulatory approval for its products in additional jurisdictions, regulatory approvals for Avivagen’s products may not be available in one or more additional jurisdictions in a timely or cost effective manner, if at all, and, if received, such approvals may not have the anticipated positive effects on the Corporation’s business and prospects.

Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:                      
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

Copyright © 2017 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

GlobeNewswire
globenewswire.com

Last updated on: 23/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.